OPEN END TURBO LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000ME5B511

Market Closed - Börse Stuttgart 19:46:14 28/06/2024 BST
15.82 EUR -1.25% Intraday chart for OPEN END TURBO LONG - UNITED THERAPEUTICS
Current month+36.03%
1 month+38.77%
Date Price Change
28/06/24 15.82 -1.25%
27/06/24 16.02 0.00%
26/06/24 16.02 -0.12%
25/06/24 16.04 +0.94%
24/06/24 15.89 +1.40%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 07:46 pm

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN ME5B51
ISINDE000ME5B511
Date issued 13/12/2023
Strike 147.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 9.8
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 16.23
Lowest since issue 6.25

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
318.6 USD
Average target price
298.9 USD
Spread / Average Target
-6.15%
Consensus